Wang Erica Hz, Marnoch Catherine A, Khurana Rshmi, Sia Winnie, Yuksel Nesé
Kelowna General Hospital, Kelowna, Canada.
Department of Medicine and Department of Obstetrics and Gynaecology, Waitemata District Health Board, Auckland, New Zealand.
Obstet Med. 2014 Jun;7(2):77-83. doi: 10.1177/1753495X14520849. Epub 2014 Feb 19.
Women with venous thromboembolism (VTE), thrombophilias or mechanical heart valves may require anticoagulation during pregnancy and postpartum. The incidence of postpartum hemorrhage (PPH) in the literature is 2.9-6%, but the rate while on anticoagulation is not well documented.
To determine the incidence of haemorrhagic complications associated with the use of peripartum anticoagulation, and the types and risk factors for haemorrhagic complications.
A retrospective chart review was conducted on women who delivered at an academic teaching hospital and received peripartum anticoagulation between January 2000 and August 2009. Women with known bleeding disorders were excluded.
In total, 195 cases were identified with mean age 31.3 years and gestational age of 37.7 weeks. Of these, 49% had a history of VTE, 21% had active VTE in the index pregnancy, and 63% had vaginal delivery. Types of anticoagulation used antepartum were unfractionated heparin (UFH) (43%) and low molecular weight heparin (LMWH) (36%), with 26% receiving therapeutic doses. The rate of haemorrhagic complications was 12.8%, with majority being PPH (80%). Sixty percent of the PPH occurred before reintroduction of anticoagulation postpartum. Use of therapeutic UFH antepartum was associated with increased risk of haemorrhagic complications compared to LMWH (OR 3.08, 95% CI 0.663 - 15.03, p = 0.183).
The rate of haemorrhagic complications is higher in women on peripartum anticoagulation compared with published incidence in unselected obstetric populations; however, this rate is similar to our institution's reported rates. Our findings inform clinicians about competing risks of thrombotic and haemorrhagic complications in this population.
患有静脉血栓栓塞症(VTE)、血栓形成倾向或机械心脏瓣膜的女性在孕期和产后可能需要进行抗凝治疗。文献中产后出血(PPH)的发生率为2.9%-6%,但抗凝治疗期间的发生率尚无充分记录。
确定围产期抗凝治疗相关出血并发症的发生率,以及出血并发症的类型和危险因素。
对2000年1月至2009年8月在一家学术教学医院分娩并接受围产期抗凝治疗的女性进行回顾性病历审查。排除已知有出血性疾病的女性。
共确定195例,平均年龄31.3岁,孕周37.7周。其中,49%有VTE病史,21%在本次妊娠中有活动性VTE,63%经阴道分娩。产前使用的抗凝类型为普通肝素(UFH)(43%)和低分子肝素(LMWH)(36%),26%接受治疗剂量。出血并发症发生率为12.8%,多数为PPH(80%)。60%的PPH发生在产后重新开始抗凝治疗之前。与LMWH相比,产前使用治疗剂量的UFH与出血并发症风险增加相关(OR 3.08,95%CI 0.663-15.03,p = 0.183)。
与未选择的产科人群中公布的发生率相比,围产期抗凝治疗女性的出血并发症发生率更高;然而,这一发生率与我们机构报告的发生率相似。我们的研究结果告知临床医生该人群中血栓形成和出血并发症的竞争风险。